Antibodies are proteins made by your body's immune system that fight off infections, including infections caused by viruses. Your body can remember how to make antibodies if you are exposed to the same germ again.
Monoclonal antibodies are just like your body's antibodies but selected for their strong ability to resist the virus. They are produced like a medication and help your body fight illness. In 2020, the Food and Drug Administration issued an emergency use authorization to permit monoclonal antibodies as a treatment option for COVID-19.
THE MONOCLONAL ANTIBODY TREATMENT PROCESS
After entering your body, monoclonal antibodies look for and attach to the spike protein that sticks out of the coronavirus that causes COVID-19.
When monoclonal antibodies attach to the spike protein, they can block the virus's ability to enter cells — and slow down the infection.
In 2020, the FDA authorized several different monoclonal antibodies to treat COVID-19.
THE EFFECTIVENESS OF MONOCLONAL ANTIBODY TREATMENT
According to a study from the New England Journal of Medicine, early clinical data show that monoclonal antibodies can successfully reduce COVID-19 hospitalization rates. Clinical trials have shown that these treatments can decrease hospitalizations and emergency department visits. They can also reduce the amount of virus found in an infected person's blood.
Health officials continue to monitor the safety and effectiveness of the treatments, and clinical trials are ongoing.
Eligibility for monoclonal antibody treatment:
Contact your doctor to be evaluated and learn if you qualify for monoclonal antibody treatment at ACMH.
A doctor’s order is required to receive treatment. Once evaluated, your provider will schedule the appointment with the infusion center, and provide you with a date and time for you to come in for your treatment. Outpatient antibody infusions are administered at the ACMH Health and Wellness Education Pavilion located at 79 Glade Drive, Kittanning, PA.